secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000834365-25-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M
------------------------------------------------------------------------

- Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).
- GAAP net loss $15.8M includes non-cash $15.5M IPR&D charge from PanTHERA acquisition.
- Non-GAAP adjusted net income $0.5M vs. loss of $1.0M a year ago; adjusted EBITDA $6.1M (24% of revenue).
- Raises FY2025 Cell Processing revenue guidance to $91-93M; total revenue guidance to $100-103M.
- Biopreservation media embedded in 16 approved therapies; over 250 ongoing trials, including 30+ Phase III.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000083436525000014/0000834365-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000083436525000014/blfs-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000834365-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer